CAR-T THERAPY ELIGIBILITY:
SECOND OPINION — CHINA VS WESTERN ACCESS

CAR-T cell therapy represents one of the most significant advances in haematological oncology of the past decade — producing durable remissions in patients with relapsed/refractory B-cell lymphoma, ALL, multiple myeloma, and other haematological malignancies that were previously considered incurable. Yet a significant proportion of eligible patients never receive CAR-T — because their treating oncologist is not at a CAR-T centre, is unaware of the current eligibility landscape, or does not know which products are available in which countries.

“CAR-T is not a last resort — it is a treatment with curative potential that is being missed by patients who were never assessed for eligibility by a specialist who delivers it.”

• Why Eligibility Is Complex

  CAR-T eligibility depends on diagnosis, number of prior lines of therapy, performance status, organ function, tumour burden, and specific molecular features — with different criteria applying to different products. A patient ineligible for one CAR-T product may be eligible for another — and a product approved in China may have broader criteria than the equivalent US or European label.

• Why China Has the Broadest Access

  China's NMPA has approved more CAR-T constructs than any regulatory agency globally — including products not yet approved in the USA or Europe. China also hosts the world's largest portfolio of investigational CAR-T clinical trials, covering targets including CD22, FLT3, CD138, GD2, and GPRC5D. For patients in China or willing to travel, the breadth of CAR-T access is unmatched.

Understanding the scale of cost and access differences between China and Western countries contextualises why a CAR-T eligibility second opinion focused on Chinese access is clinically and financially significant.

• 60–80%Cost reduction for CAR-T in China vs the USAAxicabtagene ciloleucel (Yescarta) costs approximately $370,000 per infusion in the USA — the Chinese-manufactured equivalent (CARNA, relma-cel) is available at $40,000–80,000 in China. Domestic Chinese CAR-T products are even lower cost.
• 10+NMPA-approved CAR-T products in China as of 2024China's NMPA has approved over 10 distinct CAR-T constructs — including CD19, BCMA, CD22, and dual-targeted products — compared to 6 FDA approvals and fewer EMA approvals as of the same period.
• 3rd line+Standard eligibility threshold for most approved CAR-T productsMost approved CAR-T products require ≥2 prior lines of therapy in DLBCL, ≥1 in paediatric ALL (tisagenlecleucel), and ≥3–4 in myeloma — thresholds that differ across products and between Chinese and Western labels.

The regulatory landscape for CAR-T differs meaningfully between jurisdictions — patients ineligible in one system may have access in another.

CAR-T eligibility assessment through CancerFax is structured to cover both commercially approved products and investigational trial access — across Chinese and Western regulatory landscapes.

1. 1

   Full Treatment History Review

   Assessment of all prior lines of therapy — drug names, cycles, response depth, duration of response, and reason for discontinuation. The number and nature of prior lines is the primary eligibility criterion for most approved CAR-T products.

2. 2

   Disease Status and Molecular Profile

   Current disease documentation — bone marrow biopsy, CT/PET staging, flow cytometry, and molecular markers (BCL2, MYC, CD19/22/BCMA expression, FISH for high-risk features). These determine both eligibility and product selection.

3. 3

   Performance Status and Organ Function Assessment

   CAR-T requires adequate organ function (LVEF ≥45–50%, creatinine, LFTs) and ECOG PS 0–1 for most commercial protocols. CancerFax reviews available functional data and identifies any bridging therapy requirements.

4. 4

   Cross-Jurisdictional Eligibility Mapping

   CancerFax maps the patient's profile against eligibility criteria for all relevant approved and investigational CAR-T products — in China, the USA, Europe, and Australia — identifying all potential access routes.

5. 5

   CAR-T Centre Referral and Process Coordination

   For eligible patients, CancerFax facilitates referral to the appropriate CAR-T centre — including leukapheresis scheduling, bridging therapy coordination, product manufacturing timeline planning, and in-China logistics for patients accessing Chinese products.

For patients considering CAR-T, the choice between accessing it in China versus a Western country involves cost, product breadth, waiting time, and logistical requirements — all of which differ significantly.

Frequently Asked Questions

Common questions from patients and families exploring CAR-T eligibility and access.

Explore related second opinion guides for haematological malignancies and molecular testing.